Design efficiency in dose finding studies

Computational Statistics and Data Analysis

Volumn 45, Issue 2, 2004, Pages 197-214

  Paoletti, Xavier ^a   O'Quigley, John ^b   Maccario, Jean ^a  

^a INSERM   (France)

^b INSTITUT CURIE   (France)

Author keywords

Clinical trials; Dose finding; Efficiency; Optimality; Phase I designs

Indexed keywords

DATA REDUCTION; EFFICIENCY; STANDARDS; TOXICITY;

OPTIMAL METHODS; RIVAL METHODS;

COMPUTATIONAL METHODS;

NUMERICAL METHOD;

EID: 1142304595     PISSN: 01679473     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-9473(02)00323-7     Document Type: Article

References (20)

1. Babb J. Rogatko A. Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control Statist. Med. 17 10 1998 1103-1120
2. Braun T.M. The bivariate continual reassessment method extending the CRM to phase I trials of two competing outcomes Control Clin. Trials 23 3 2002 240-256
3. Durham S.D. Flournoy N. Random walks for quantile estimation Berger J.O. Gupta S.S. Statistical Decision Theory and Related Topics V 1994 467-476 Springer New York
4. Faries D. Practical modifications of the CRM for phase I cancer study J. Biopharm. Statist. 4 1994 147-164
5. Gasparini M. Eisele J. On curve-free method for phase I clinical trials Biometrics 56 2000 609-615
6. Goodman S.N. Zahurak M.L. Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies Statist. Med. 14 11 1995 1149-1161
7. Gooley T.A. Martin P.J. Fisher L.D. Pettinger M. Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation Controlled Clin. Trials 15 1994 450-462
8. Legedza A.T. Ibrahim J.G. Longitudinal design for phase I clinical trials using the continual reassessment method Control Clin. Trials 21 6 2000 574-588
9. Møller S. An extension of the CRM using a preliminary up and down design in a dose finding study in cancer patients, in order to investigate a greater range of doses Statist. Med. 14 1995 922-991
10. O'Quigley J. Paoletti X. Maccario J. Non-parametric optimal design in dose finding studies Biostatistique 3 2002 51-56
11. O'Quigley J. Pepe M. Fisher L. Continual reassessment method: a practical design for phase I clinical studies in cancer Biometrics 46 1990 33-48
12. O'Quigley J. Reiner E. A stopping rule for the continual reassessment method Biometrika 85 1998 741-748
13. O'Quigley J. Shen Z.L. Continual reassessment method: a likelihood approach Biometrics 52 1996 163-174
14. O'Quigley J. Shen Z.L. Gamst A. Two sample continual reassessment method J. Biopharm. Statist. 9 1 1999 17-44
15. Paoletti, X., 2001. Phase I clinical trials in oncology: optimality, efficiency and reliability in various situations. Ph.D. Dissertation, University Paris-V René Descartes.
16. Piantadosi S. Liu G. Improved designs for dose escalation studies using pharmacokinetics measurements Statist. Med. 15 1996 1605-1618
17. Storer B.E. Design and analysis of phase I clinical trials Biometrics 45 1989 925-937
18. Thall P.F. Russel K.E. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials Biometrics 54 1998 251-264
19. Whitehead J. Bayesian decision procedures with application to dose-finding studies Internat. J. Pharm. Med. 11 1997 201-208
20. Zee B. Melnychuk D. Dancey J. Eisenhauer E. Multinomial phase II cancer trials incorporating response and early progression J. Biopharm. Statist. 9 2 1999 351-363